{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T14:22:34Z","timestamp":1717597354276},"reference-count":82,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,3,14]],"date-time":"2016-03-14T00:00:00Z","timestamp":1457913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Approximately 350 million people worldwide are chronically infected with hepatitis B virus (<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>), representing a significant public health challenge. Nucleos\/tide analogues (<jats:styled-content style=\"fixed-case\">NUC<\/jats:styled-content>s) and interferon alpha (<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>\u03b1), the current standard of care for chronic infection, aim at preventing progression of the disease to cirrhosis, hepatocellular carcinoma (<jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content>) and death. However, in contrast to the case of hepatitis C virus infection, in which novel antiviral drugs cure the vast majority of treated patients, in regard to <jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>, cure is rare due to the unusual persistence of viral <jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content> in the form of covalently closed circular <jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content> (ccc<jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content>) within the nucleus of infected cells. Available therapies for <jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content> require lifelong treatment and surveillance, as reactivation frequently occurs following medication cessation and the occurrence of <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content> is decreased but not eliminated, even after years of successful viral suppression. Progress has been made in the development of new therapeutics, and it is likely that only a combination of immune modulators, inhibitors of gene expression and replication and ccc<jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content>\u2010targeting drugs will eradicate chronic infection. This review aims to summarize the state of the art in <jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content> drug research highlighting those agents with the greatest potential for success based on <jats:italic>in vitro<\/jats:italic> as well as on data from clinical studies.<\/jats:p>","DOI":"10.1111\/liv.13086","type":"journal-article","created":{"date-parts":[[2016,2,8]],"date-time":"2016-02-08T11:43:02Z","timestamp":1454931782000},"page":"775-782","source":"Crossref","is-referenced-by-count":20,"title":["New therapies for chronic hepatitis B"],"prefix":"10.1111","volume":"36","author":[{"given":"Maya","family":"Bitton Alaluf","sequence":"first","affiliation":[{"name":"Department of Medicine D Beilinson Hospital Rabin Medical Center Petah Tikva Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Shlomai","sequence":"additional","affiliation":[{"name":"Department of Medicine D Beilinson Hospital Rabin Medical Center Petah Tikva Israel"},{"name":"The Liver Institute Beilinson Hospital Rabin Medical Center Petah Tikva Israel"},{"name":"The Sackler Faculty of Medicine Tel\u2010Aviv University Tel\u2010Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,3,14]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra031087"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1001683"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.1.65"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26180"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12344"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04869.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12078"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.71.4.565"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-4-199308150-00011"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043470"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.03.006"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17701-0"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00249-15"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.06.008"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.01.006"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.10.011"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802878"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21282"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5415.825"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.06.014"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28025"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/35888"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt824"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50146"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2004.0960.x"},{"key":"e_1_2_8_27_1","first-page":"707A","article-title":"ARC\u2010520 RNAi therapeutic reduces hepatitis B virus DNA, S antigen and e antigen in a chimpanzee with a very high viral titer","volume":"58","author":"Lanford RE","year":"2013","journal-title":"Hepatology"},{"key":"e_1_2_8_28_1","first-page":"1280A","article-title":"Phase II, dose ranging study of ARC\u2010520, a siRNA\u2010based therapeutic, in patients with chronic hepatitis B virus infection","volume":"60","author":"Yuen MF","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_8_29_1","first-page":"163","volume-title":"Methods Mol Biol","author":"Sebesty\u00e9n M","year":"2015"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.06.020"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1077215"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409732102"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30134-3"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30845-X"},{"key":"e_1_2_8_35_1","first-page":"1279A","article-title":"Phase 1a safety and pharmacokinetics of NVR 3\u2010778, a potential first\u2010in\u2010class HBV core inhibitor","volume":"60","author":"Gane EJ","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1513803112"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.04.002"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.12.024"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00049"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1389"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.12.008"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1159\/000360948"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.030"},{"key":"e_1_2_8_44_1","first-page":"1279A","article-title":"A proof\u2010of\u2010concept Phase 2a clinical trial with HBV\/HDV entry inhibitor Myrcludex B","volume":"60","author":"Bogomolov P","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2015.06.016"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.07.014"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0401771101"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12749"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301073"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.3109\/08830185.2013.774391"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.026"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.02.037"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12305"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04321-14"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1939"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604808"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.18.1365"},{"key":"e_1_2_8_58_1","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.4049\/jimmunol.152.10.4976","article-title":"MHC class I and non\u2010MHC\u2010linked capacity for generating an anti\u2010viral CTL response determines susceptibility to CTL exhaustion and establishment of virus persistence in mice","volume":"152","author":"Moskophidis D","year":"1994","journal-title":"J Immunol"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80628-7"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.10.009"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.09.072"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.07.027"},{"key":"e_1_2_8_63_1","first-page":"1181A","article-title":"Safety and efficacy of GS\u20104774 in patients with chronic hepatitis B on oral antiviral therapy","volume":"62","author":"Lok ASF","year":"2015","journal-title":"Hepatology"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.08.013"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-305707"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000088"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.5.2714"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02844-06"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2012.0320"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003856"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1409986111"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128401"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2014.03.011"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2014.12.001"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.38"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep10833"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.68"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2015.2"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14299"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00473-12"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01123-07"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.004861-0"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1243462"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.13086","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.13086","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.13086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T13:34:34Z","timestamp":1695562474000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.13086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,14]]},"references-count":82,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1111\/liv.13086"],"URL":"https:\/\/doi.org\/10.1111\/liv.13086","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,14]]}}}